<sup>131</sup>I标记卟啉化合物结合光动力治疗对肿瘤生长的抑制作用

¹³¹I标记卟啉化合物结合光动力治疗对肿瘤生长的抑制作用

摘要: 利用放射性核素¹³¹I标记了卟啉化合物TPPOH和TPPNH₂得到¹³¹I-TPPOH和¹³¹I-TPPNH₂。建立了接种人肝癌细胞系SMMC-7721的裸鼠皮下肿瘤模型。将¹³¹I-TPPOH和¹³¹I-TPPNH₂直接注入肿瘤，考察了卟啉化合物、¹³¹I和光照对肿瘤生长的抑制效果。结果显示，¹³¹I-TPPOH和¹³¹I-TPPNH₂在注射14 d后仍大量滞留在肿瘤组织中。在β射线和光动力的双重作用下，两种¹³¹I标记的卟啉化合物均表现出对肿瘤生长较强的抑制能力。以上结果提示，基于“卟啉+¹³¹I+光动力治疗”结合的概念可开发一种新的实体肿瘤治疗剂。

Abstract: The porphyrins of TPPOH and TPPNH₂ were labeled with ¹³¹I to obtain ¹³¹I-TPPOH and ¹³¹I-TPPNH₂. The human hepatocellular carcinoma cell line SMMC-7721 bearing nude mice was developed. The labeled compounds were injected into tumors directly to investigate the antiblastic effect of porphyrin, ¹³¹I and photodynamic therapy (PDT) to tumor. ¹³¹I-TPPOH and ¹³¹I-TPPNH₂ still remain in tumors after 14 d post injection, and it shows that the two porphyrins have good affinity to tumors. By the function of β-ray and PDT, the two ¹³¹I labeled porphyrins show a very effective antiblastic effect to tumors. It is possible to develop a novel solid tumor therapy ligand combined “porphyrin+¹³¹I+PDT”.